Patient Community Events

Informational Webcast on Avapritinib Clinical Trial Program in Systemic Mastocytosis (SM)

On Tuesday, September 18, 2018, The Mastocytosis Society and Blueprint Medicines hosted a webinar for the systemic mastocytosis (SM) community about avapritinib (also known as BLU-285), an investigational medicine for people with SM.

Dr. Andy Boral, Chief Medical Officer at Blueprint Medicines, shared an update on recently presented clinical results, as well as plans for future studies in advanced, indolent and smoldering forms of SM.

A replay of the webcast is available by clicking below:

Patients who are interested in the planned studies can contact the Blueprint Medicines study director at studydirector@blueprintmedicines.com or 1-617-714-6707 to learn more about opportunities to participate. Additional information about the PATHFINDER trial is available at pathfindertrial.com or https://clinicaltrials.gov/ct2/show/NCT03580655.